Shots:

• The P-III PANORAMA study involves assessing Eylea [inj. 2mg (0.05ml)- q8w/q16w] vs sham in 402 patients with moderately severe to severe NPDR without DME
• The P-III PANORAMA study results: @2yrs. 75% reduction in vision-threatening events- patients demonstrated greater improvement in the DRSS score from baseline (80% @52wks and 50% @100 wks.) in q8w group while >2-step DRSS scores remained consistent (65% @52 wks. vs 62% @100 wks.) in q16w group
• Eylea is a VEGF inhibitor targeting VEGF-A and PLGF- formulated as an injection for the eye- act by blocking the growth of new blood vessels and by decreasing vascular permeability in the eye and is approved therapy for Wet AMD- macular edema following RVO- DME and DR in the US 

Click here ­to­ read full press release/ article | Ref: Regeneron | Image: StraitTimes